A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

  • End date
    Jun 30, 2022
  • participants needed
  • sponsor
    Merck Sharp & Dohme Corp.
Updated on 12 September 2021


This study will evaluate the safety, tolerability, and efficacy of tedizolid phosphate (MK-1986) compared with comparator antibacterial agent in participants from birth to less than 12 years of age with acute bacterial skin and skin structure infections (ABSSSI).


Participants will be randomized (3:1) to receive tedizolid phosphate at a weight-based dose 200 mg/day, intravenous (IV) and/or oral suspension for 6 to 10 days, or comparator IV and/or oral per local standard of care for 10 to 14 days. The switch from IV to oral administration can be made at any time based on 1) no worsening of the primary skin lesion, 2) last temperature <37.7 C, and 3) primary acute bacterial skin and skin structure infection (ABSSSI) site has not worsened and at least 1 site has improved from Baseline. The potential 4-day treatment extension will be based on clinical need as judged by the investigator, considering the following criteria: 1) 40% reduction in primary lesion size, 2) reduction in pain, and 3) no new signs and symptoms and no complications attributable to ABSSSI compared with Baseline.

Condition Acute Bacterial Skin and Skin Structure Infections
Treatment Comparator, MK-1986, Tedizolid phosphate
Clinical Study IdentifierNCT03176134
SponsorMerck Sharp & Dohme Corp.
Last Modified on12 September 2021


Yes No Not Sure

Inclusion Criteria

Has a parent/legally acceptable representative who is able to give documented informed consent
Has ABSSSI, defined as 1 of the following: 1) cellulitis/erysipelas, 2) major cutaneous abscess, or 3) wound infection
Local symptoms of ABSSSI that started within 14 days before study start
Suspected or documented Gram-positive bacterial infection
Body weight 3.2 kg

Exclusion Criteria

Uncomplicated skin and skin structure infection
ABSSSI due to or associated with disallowed etiology per protocol
Received antibacterial therapy for treatment of the current episode of ABSSSI except
<24 hours of antibacterial therapy with a short-acting antibacterial drug, or 2) response is considered to be failure (no improvement in signs and symptoms) after at least 48 hours of therapy
Known bacteremia, severe sepsis, or septic shock
Significant or life-threatening condition, disease, or organ system condition
Recent history of opportunistic infections where the underlying cause of the infection is still active, or is suspected to be at risk of opportunistic infection with unusual pathogens
Received or is receiving treatment for active tuberculosis within 1 month of study start
Known or suspected severe neutropenia
Human immunodeficiency virus (HIV) positive and has Cluster of Differentiation (CD) 4 cell count <15% (HIV testing is not required for eligibility)
Renal impairment that requires renal filtration
Severe hepatic impairment
Cardiac or electrocardiogram (ECG) finding that would limit participation in the study
Received an investigational medicinal product (not approved) within 30 days before study start
Investigational device present or removed within 30 days before study start
Previously treated with tedizolid phosphate
Contraindication, including hypersensitivity to tedizolid phosphate, other oxazolidinones, or any component in the formulation
Contraindication, including hypersensitivity to all available comparator drugs
Wound infection and history of hypersensitivity to aztreonam adjunctive therapy or metronidazole adjunctive therapy, if adjunctive therapy is required
Needs oral administration of methotrexate, topotecan, irinotecan, or rosuvastatin, during administration of oral study drug (administration during the follow-up period, ie, after the EOT visit, is allowed, as is administration during treatment with IV drug)
Female who is pregnant or nursing or is of childbearing potential and not abstinent; or male who is not abstinent
Use of monoamine oxidase inhibitors, tricyclic antidepressants, buspirone, selective serotonin reuptake inhibitors, or serotonin 5-hydroxytryptamine receptor agonists (triptans)
Identified as having used illicit drugs (urine drug screening not required for entry)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note